Molecule News and Research

RSS

Compugen's Antibody Target Discovery Platform presented at 7th Annual European Antibody Congress

Speaking today at the plenary session of the 7th Annual European Antibody Congress in Geneva, Dr. Anat Cohen-Dayag, President and CEO of Compugen Ltd., presented Compugen's Antibody Target Discovery Platform, one of the Company's predictive discovery platforms for novel therapeutic targets.

1 Dec 2011

Researchers reveal ambivalent role of CXCL12/CXCR4 molecule in myocardial infarction

The chemokine CXCL12 acts as a chemical signal which mobilizes hematopoietic and other types of stem cells to leave the bone marrow and enter the circulation. Secretion of CXCL12 also guides these cells to sites at which the perfusion of tissue is sub-optimal due to localized obstruction of blood flow. These capabilities have made CXCL12 and its cognate receptor CXCR4 interesting candidates for therapies aimed at mitigating the effects of damage to the heart caused by myocardial infarction.

1 Dec 2011

Lapatinib could extend survival in women with Her2-positive breast cancer

Treatment with lapatinib could extend survival in women with Her2-positive breast cancer that has spread to the brain, according to research published in the British Journal of Cancer.

30 Nov 2011

BioLineRx reports third quarter net loss of NIS 7.9 million

BioLineRx Ltd., a biopharmaceutical development company, today reported its results for the third quarter ending September 30, 2011.

29 Nov 2011

New technique to accomplish 'accelerated serendipity' using robotics

Scientists can now take that "a-ha" moment to go with a method Princeton University researchers developed - and successfully tested - to speed up the chances of an unexpected yet groundbreaking chemical discovery.

29 Nov 2011

Scientists identify cellular protein that plays central role in formation of new blood vessels

Scientists at the University of North Carolina at Chapel Hill School of Medicine have identified a cellular protein that plays a central role in the formation of new blood vessels.

29 Nov 2011

Scientists use genetic methods to successfully repair cleft lips in mice embryos

Scientists at Weill Cornell Medical College used genetic methods to successfully repair cleft lips in mice embryos specially engineered for the study of cleft lip and cleft palate. The research breakthrough may show the way to prevent or treat the conditions in humans.

29 Nov 2011

Corkscrew structure inspires new weapon against E-coli and MRSA

Scientists at the University of Warwick have taken inspiration from corkscrew structures found in nature to develop a new weapon in the fight against infections like E-coli and MRSA.

28 Nov 2011

Enrollment complete in SUSTAIN Phase 2b clinical trial for atherosclerotic CVD

Resverlogix Corp. today announced that SUSTAIN, a Phase 2b clinical trial comprised of 176 subjects, is fully enrolled.

28 Nov 2011

Novel proteomics based method detects inhibition of intracellular deubiquitylating enzymes

Researchers at the University of Oxford and Progenra, Inc. are pleased to announce the publication of a research article entitled "Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes" that details a novel proteomics based method to detect inhibition of intracellular deubiquitylating enzymes (DUBs).

28 Nov 2011

New creative uses of DNA 'barcoding'

The newfound scientific power to quickly "fingerprint" species via DNA is being deployed to unmask quack herbal medicines, reveal types of ancient Arctic life frozen in permafrost, expose what eats what in nature, and halt agricultural and forestry pests at borders, among other applications across a wide array of public interests.

28 Nov 2011

Knocking out one copy of IGF1 receptor fails to increase life span of male mice

Scientists studying longevity thought it might be good to lack a copy of a gene, called IGF1 receptor, that is important in insulin signaling. Previous studies showed invertebrates that lacked the copy lived longer, even if their bodies were less responsive to insulin, the hormone that lowers blood sugar.

24 Nov 2011

Study reveals principal mechanism of action for paracetamol

Researchers at King's College London have discovered how one of the most common household painkillers works, which could pave the way for less harmful pain relief medications to be developed in the future.

23 Nov 2011

New procedure could be adapted for use with X-ray techniques in studying human health

For more than a century, the use of X-rays has been a prime diagnostic tool when it comes to human health. As it turns out, X-rays also are a crucial component for studying and understanding molecules, and a new approach -- just published by researchers at the University of Georgia -- may dramatically improve what researchers can learn using the technique.

23 Nov 2011

Scientists identify new immune system defect in aged mice

As people age, their immune system becomes less robust. This makes them more susceptible to serious and frequently life-threatening infections with viruses that affect the respiratory tract such as influenza A virus.

22 Nov 2011

New way to enhance effects of anandamide in the body

UC Irvine and Italian researchers have discovered a new means of enhancing the effects of anandamide - a natural, marijuana-like chemical in the body that provides pain relief.

22 Nov 2011

Researchers manipulate life span of yeast by mutating chemical residues

Collaborations between Johns Hopkins and National Taiwan University researchers have successfully manipulated the life span of common, single-celled yeast organisms by figuring out how to remove and restore protein functions related to yeast aging.

22 Nov 2011

Targeting synthetic RNA to specific gene could help reduce severity of SMA

A team of University of Missouri researchers have found that targeting a synthetic molecule to a specific gene could help the severity of the disease Spinal Muscular Atrophy (SMA) - the leading genetic cause of infantile death in the world.

22 Nov 2011

Nature Medicine publishes dexpramipexole Phase 2 ALS study results

Knopp Biosciences LLC today announced the publication in Nature Medicine of comprehensive results from the Phase 2 study of dexpramipexole, a small-molecule modulator of mitochondrial bioenergetics, in people with amyotrophic lateral sclerosis.

21 Nov 2011

Akebia commences dosing in AKB-9778 Phase 1 study for diabetic macular edema and retinopathy

Akebia Therapeutics, Inc., a small molecule discovery and development company focused on anemia and vascular disorders, today announced that it has dosed the first subjects in a first-in-man Phase 1 study of AKB-9778, a first-in-class human protein tyrosine phosphatase beta (HPTPβ) inhibitor in development for diabetic macular edema (DME) and diabetic retinopathy (DR).

21 Nov 2011